How to Help Your Patients Save Money on Emsam: A Provider's Guide to Savings Programs

Cost is among the most significant barriers to Emsam (selegiline transdermal system) access. At a retail price of $2,600–$2,800 per month with no generic available, even insured patients can face substantial out-of-pocket expenses. As a prescriber, understanding the full landscape of savings programs and financial assistance options allows you to proactively support your patients in maintaining access to this medication.

This guide covers every major savings pathway for Emsam in 2026, with eligibility details, enrollment steps, and recommendations for different patient scenarios.

Why Emsam Cost Is a Clinical Problem

When cost prevents a patient from filling a psychiatric medication, the consequences are not merely financial — they are clinical. For Emsam patients specifically, the risks of cost-driven non-adherence include:

Return or worsening of major depressive symptoms

Dangerous medication transitions: patients who self-initiate another antidepressant without a proper MAOI washout risk serotonin syndrome

Increased psychiatric crisis risk and hospitalization

Proactively connecting patients with savings resources at the time of prescribing — before a coverage problem arises — is best practice.

Program 1: Emsam Savings Card (For Commercially Insured Patients)

The Viatris Advocate Emsam Savings Card is the most impactful cost-reduction tool available for commercially insured Emsam patients.

Patient cost: As little as $20 per monthly fill after patient pays first $20

Maximum benefit: Up to $600 savings per fill; $7,200 maximum per calendar year

Uses: Up to 12 fills per year

Eligibility: Commercial insurance only; excludes Medicare, Medicaid, VA, TRICARE, and uninsured patients

Enrollment: Patient registers at activatethecard.com/emsam; presents card at pharmacy. No income verification required.

Clinical recommendation: Have a printed information card or QR code linking to the Savings Card program available in your waiting room or exam room. Mention it at every new Emsam initiation.

Program 2: Patient Assistance Programs (PAPs) for Uninsured and Underinsured Patients

For patients without commercial insurance or with coverage that doesn't adequately cover Emsam, manufacturer patient assistance programs and enrollment advocacy organizations provide income-based access:

Prescription Hope (prescriptionhope.com): Works with manufacturer PAPs to provide Emsam for approximately $70/month for eligible patients. Works with any coverage. First delivery typically within 2 weeks of approval. No application fee unless medication is secured.

The Rx Advocates (therxadvocates.com): Enrolls patients directly in manufacturer PAPs. Emsam for approximately $80/month. Income criteria typically include individual income under ~$40,000/year or household income under applicable limits. The Rx Advocates handles enrollment paperwork, prescriber coordination, and ongoing refill management.

Your clinical staff can facilitate PAP enrollment by:

Completing the prescriber section of the PAP application (name, NPI, DEA number, diagnosis, Rx)

Responding promptly to requests for additional clinical documentation

Tracking PAP application status alongside other prior authorization management in your EHR workflow

Program 3: Prior Authorization Appeals and Formulary Exceptions

When insurance denies or places Emsam on an excessively high cost-sharing tier, a well-documented appeal or formulary exception request can significantly reduce patient costs. Key strategies:

Non-formulary exception: Request that Emsam be covered at a preferred tier rate by documenting that the patient has failed clinically adequate trials of formulary alternatives and has clinical features (atypical depression, treatment-resistant course) that specifically indicate MAOI/Emsam.

Step therapy exception: If the plan requires more prior antidepressant failures than the patient has experienced, document why Emsam is medically necessary now — for example, a contraindication to the next required step drug (e.g., serotonin syndrome history), or significant clinical decompensation that makes further delays clinically inappropriate.

Peer-to-peer review: Direct conversation with the plan's medical director is often more effective than written appeals for Emsam. Frame the clinical case around what makes this patient specifically appropriate for MAOI therapy and why alternatives are inadequate.

Medicare-Specific Guidance

Medicare patients face specific challenges because the manufacturer Savings Card is not available for Medicare beneficiaries. For elderly patients on Emsam:

File a Part D coverage determination or exception request to move Emsam to a lower cost-sharing tier, citing medical necessity

Refer income-eligible patients to the Extra Help (Low Income Subsidy) program, which can significantly reduce Part D cost sharing

Consider referring very low-income Medicare patients to PAP advocacy programs (Prescription Hope, Rx Advocates) which may have workarounds for Medicare-eligible patients depending on circumstances

Building a Systematic Savings Program Into Your Emsam Prescribing Protocol

Practices with the highest Emsam adherence rates typically integrate cost assistance into their prescribing workflow from day one. Consider:

Creating a one-page Emsam patient handout that includes the Savings Card URL, PAP contact information, and pharmacy routing guidance

Tasking a clinical staff member with initiating PA and Savings Card enrollment at the same time the prescription is written

Scheduling a follow-up contact 7–10 days after prescribing to confirm the patient successfully filled their prescription and is enrolled in a savings program

For providers whose patients struggle to physically locate pharmacies that carry Emsam, medfinder for providers can help patients find which pharmacies near them can fill their prescription, removing one more barrier to consistent access.

See also: How to Help Your Patients Find Emsam in Stock: A Provider's Guide.